Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Clinical Oncology

• Publication date

  1998-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1998.16.3.1068PMID 9508192
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice

  2004cited by this paper
• Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.

  1995cited by this paper
• Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

  1994cited by this paper
• Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.

  1994cited by this paper
• Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.

  1994cited by this paper
• Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.

  1994cited by this paper
• Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group.

  1994cited by this paper
• Limited stage small cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/cisplatin

  1993cited by this paper
• Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.

  1993cited by this paper
• Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts

  1993cited by this paper
• Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.

  1993cited by this paper
• Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group.

  1993cited by this paper
• Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

  1992cited by this paper
• A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

  1992cited by this paper
• CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.

  1992cited by this paper
• CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

  1992cited by this paper
• Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.

  1991cited by this paper
• Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.

  1991cited by this paper
• Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study.

  1990cited by this paper
• Thoracic radiotherapy variables: influence on local control in small cell lung cancer limited disease.

  1990cited by this paper
• Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.

  1987cited by this paper
• A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

  1987cited by this paper
• Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.

  1987cited by this paper
• Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.

  1987cited by this paper
• Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada.

  1987cited by this paper
• Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

  1985cited by this paper
• VP-16 and cisplatin as first-line therapy for small-cell lung cancer.

  1985cited by this paper
• Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop.

  1983cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1980cited by this paper
• cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung.

  1979cited by this paper

• Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study

  2023cites this paper
• History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature

  2021cites this paper
• A systematic review of survival following anti-cancer treatment for small cell lung cancer.

  2020cites this paper
• Current Practices and Awareness of Anticancer Plants in the Traditional Healthcare System

  2018cites this paper
• Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer

  2018cites this paper
• The long story of camptothecin: From traditional medicine to drugs.

  2017cites this paper
• Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer

  2017cites this paper
• Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand?

  2017cites this paper
• Chapter 10 – Lung Cancer

  2017cites this paper
• Therapies in the pipeline for small-cell lung cancer.

  2016cites this paper
• Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.

  2015cites this paper
• Etirinotecan Pegol: Development of a Novel Conjugated Topoisomerase I Inhibitor

  2014cites this paper
• Neoadjuvant chemotherapy followed by D2 gastrectomy and esophagojejunal Roux-en-Y anastomosis in gastric small cell carcinoma: A case report

  2014cites this paper
• Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.

  2014cites this paper
• Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer

  2013influential citation
• Systemic therapy for small cell lung cancer.

  2013cites this paper
• Successful combination chemotherapy with irinotecan hydrochloride and cisplatin for primary gastric small cell carcinoma: report of a case

  2013cites this paper
• Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer

  2013cites this paper
• Bicarbonate Attenuates Irinotecan-Induced Cytotoxicity through Regulation of Both Extracellular and Intracellular pHs in Intestine Cell Line

  2013cites this paper
• Two Cases of Small Cell Cancer of the Maxillary Sinus Treated with Cisplatin plus Irinotecan and Radiotherapy

  2013cites this paper
• Combination of Irinotecan and a Platinum Agent for Poorly Differentiated Neuroendocrine Carcinomas

  2013cites this paper
• Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer.

  2013cites this paper
• Association of ABCC 2 Genotype with Ef fi cacy of First-line FOLFIRI in Japanese Patients with Advanced Colorectal Cancer

  2012cites this paper
• Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer

  2012cites this paper
• Small Cell Carcinoma of the Hypopharynx : A Case Report

  2012cites this paper
• Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.

  2012cites this paper
• Chemotherapy for small cell lung cancer: a comprehensive review

  2012cites this paper
• Herb-Drug Interactions

  2012cites this paper
• Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.

  2012cites this paper
• Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer

  2012cites this paper
• A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.

  2012cites this paper
• Molecular structure and vibrational spectra of Irinotecan: a density functional theoretical study.

  2012cites this paper
• Modern Management of Small-Cell Lung Cancer

  2012cites this paper
• Small cell carcinoma of gastro-oesophageal junction with remarkable response to chemo-radiotherapy

  2012cites this paper
• Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid

  2011cites this paper
• Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer.

  2011cites this paper
• Topoisomerase I Inhibitors – The Camptothecins

  2011cites this paper
• Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.

  2011cites this paper
• Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer

  2011cites this paper
• Phase II Study of Weekly Irinotecan plus Cisplatin in Patients with Previously Untreated Extensive-Stage Extrapulmonary Small Cell Carcinoma

  2011cites this paper
• Herbal interactions with anticancer drugs: mechanistic and clinical considerations.

  2010cites this paper
• Toxicology, Safety and Herb–drug Interactions in Cancer Therapy

  2010cites this paper
• Irinotecan and cisplatin vs. cyclophosphamide, doxorubicin, and vincristine as second-line treatment after platinum and etoposide in small-cell lung cancer.

  2010cites this paper
• Pharmacogenetics of irinotecan disposition and toxicity: a review.

  2010cites this paper
• Pharmacometric modeling of anti-cancer agents: Application to gemcitabine, PQIP and irinotecan

  2010cites this paper
• A Phase I Study of Topotecan Plus Carboplatin for Relapsed SCLC: WJTOG Trial

  2009cites this paper
• Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.

  2009cites this paper
• Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC)

  2009cites this paper
• Dose Escalation Study of Amrubicin in Combination with Fixed-Dose Irinotecan in Patients with Extensive Small-Cell Lung Cancer

  2008cites this paper
• Significance of anemia in cancer chemotherapy

  2008cites this paper
• Phase II Study of a 3-Week Schedule of Irinotecan Combined with Cisplatin in Previously Untreated Extensive-Stage Small-Cell Lung Cancer

  2008cites this paper
• Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience.

  2008cites this paper
• Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan

  2008cites this paper
• Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive Disease Small Cell Lung Cancer

  2008cites this paper
• Extensive-stage small-cell lung cancer: evolution of systemic therapy and future directions.

  2008cites this paper
• Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited‐disease small‐cell lung cancer

  2007cites this paper
• Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: Use Patterns among American Medical Oncologists 2000–2006

  2007cites this paper
• Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy.

  2007cites this paper
• A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort.

  2007cites this paper
• A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer

  2007cites this paper
• Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer.

  2007cites this paper
• Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.

  2007cites this paper
• Phase II Clinical Trial for Prevention of Delayed Diarrhea with Cholestyramine/Levofloxacin in the Second-Line Treatment with Irinotecan Biweekly in Patients with Metastatic Colorectal Carcinoma

  2007cites this paper
• Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

  2007cites this paper
• Complete remission of ovarian small cell carcinoma treated with irinotecan and cisplatin: a case report.

  2007cites this paper
• Serum Total Bilirubin as a Predictive Factor for Severe Neutropenia in Lung Cancer Patients Treated with Cisplatin and Irinotecan

  2007cites this paper
• ACCP Evidence-Based Clinical Practice : * Management of Small Cell Lung Cancer

  2007cites this paper
• A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer

  2007cites this paper
• A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.

  2006cites this paper
• Cytochrome P450 and anticancer drugs.

  2006cites this paper
• Enhancement of DNA topoisomerase I inhibitor–induced apoptosis by ursodeoxycholic acid

  2006cites this paper
• Novel Cytotoxic Agents in the Management of Lung Cancer

  2006cites this paper
• Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.

  2006cites this paper
• Phase II Trial of Irinotecan plus Cisplatin Combination as First Line Therapy for Patients with Small cell Lung Cancer

  2006cites this paper
• Phase II Study of Irinotecan Plus Cisplatin as First Line therapy in Extensive Small-Cell Lung Cancer

  2006cites this paper
• Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.

  2006cites this paper
• A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors

  2006cites this paper
• Management of small cell lung cancer

  2006cites this paper
• Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.

  2006cites this paper
• Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer

  2006cites this paper
• Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations

  2006cites this paper
• Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer

  2006influential citation
• GEFITINIB (IRESSA) INHIBITS THE CYP3A4-MEDIATED FORMATION OF 7-ETHYL-10-(4-AMINO-1-PIPERIDINO)CARBONYLOXYCAMPTOTHECIN BUT ACTIVATES THAT OF 7-ETHYL-10-[4-N-(5-AMINOPENTANOIC ACID)-1-PIPERIDINO]CARBONYLOXYCAMPTOTHECIN FROM IRINOTECAN

  2005cites this paper
• St. John’s Wort Modulates the Toxicities and Pharmacokinetics of CPT-11 (Irinotecan) in Rats

  2005cites this paper
• Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins

  2005cites this paper
• Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.

  2005cites this paper
• Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer

  2005cites this paper
• A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer

  2005cites this paper
• Pilot Study of Concurrent Etoposide and Cisplatin Plus Accelerated Hyperfractionated Thoracic Radiotherapy Followed by Irinotecan and Cisplatin for Limited-Stage Small Cell Lung Cancer: Japan Clinical Oncology Group 9903

  2005cites this paper
• Novel agents that potentially inhibit irinotecan-induced diarrhea.

  2005cites this paper
• Abstracts

  2005cites this paper
• An Interethnic Comparison of Polymorphisms of the Genes Encoding Drug-Metabolizing Enzymes and Drug Transporters: Experience in Singapore

  2005cites this paper
• A Case of Small-Cell Lung Cancer Producing Ectopic Anti-Diuretic and Adrenocorticotropic Hormones

  2005cites this paper
• Management of Small Cell Lung Cancer

  2005cites this paper
• Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.

  2005cites this paper
• Camptothecins in the Treatment of Lung Cancer

  2005cites this paper
• Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.

  2005cites this paper
• Use of Camptothecins in the Treatment of Leukemia and Related Disorders

  2005cites this paper
• Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance

  2005cites this paper
• Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.

  2005cites this paper